Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach
Raquel Villuendas, J. L. Steegmann, Marina Pollán, et al.
Leukemia (2006) Vol. 20, Iss. 6, pp. 1047-1054
Closed Access | Times Cited: 108

Showing 1-25 of 108 citing articles:

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
Michele Baccarani, Jorge E. Cortés, Fabrizio Pane, et al.
Journal of Clinical Oncology (2009) Vol. 27, Iss. 35, pp. 6041-6051
Open Access | Times Cited: 1311
Tyrosine Phosphatase PTPN22: Multifunctional Regulator of Immune Signaling, Development, and Disease
Nunzio Bottini, Erik Peterson
Annual Review of Immunology (2013) Vol. 32, Iss. 1, pp. 83-119
Open Access | Times Cited: 208
Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance
Raquel Alves, Ana Cristina Gonçalves, Sergio Rutella, et al.
Cancers (2021) Vol. 13, Iss. 19, pp. 4820-4820
Open Access | Times Cited: 119
Molecular signature of CD34+ hematopoietic stem and progenitor cells of patients with CML in chronic phase
Elena Diaz-Blanco, Ingmar Bruns, Frank Neumann, et al.
Leukemia (2007) Vol. 21, Iss. 3, pp. 494-504
Closed Access | Times Cited: 141
A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib
Shannon K. McWeeney, Lucy Pemberton, Marc Loriaux, et al.
Blood (2009) Vol. 115, Iss. 2, pp. 315-325
Open Access | Times Cited: 122
Predictors of Primary Imatinib Resistance in Chronic Myelogenous Leukemia Are Distinct From Those in Secondary Imatinib Resistance
Wenyong W. Zhang, Jorge E. Cortés, Hui Yao, et al.
Journal of Clinical Oncology (2009) Vol. 27, Iss. 22, pp. 3642-3649
Open Access | Times Cited: 110
Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population
Mizuho Fukunaga‐Kalabis, G. Martinez, Thiennga K. Nguyen, et al.
Oncogene (2010) Vol. 29, Iss. 46, pp. 6115-6124
Open Access | Times Cited: 90
Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors
Sébastien Grosso, Alexandre Puissant, Maeva Dufies, et al.
Molecular Cancer Therapeutics (2009) Vol. 8, Iss. 7, pp. 1924-1933
Open Access | Times Cited: 79
A novel isoform of the B cell tyrosine kinase BTK protects breast cancer cells from apoptosis
Cheryl Eifert, Xianhui Wang, Leila Kokabee, et al.
Genes Chromosomes and Cancer (2013) Vol. 52, Iss. 10, pp. 961-975
Open Access | Times Cited: 57
SOCS2 Controls Proliferation and Stemness of Hematopoietic Cells under Stress Conditions and Its Deregulation Marks Unfavorable Acute Leukemias
Caterina Vitali, Claudia Bassani, Claudia Chiodoni, et al.
Cancer Research (2015) Vol. 75, Iss. 11, pp. 2387-2399
Open Access | Times Cited: 54
Bruton’s Tyrosine Kinase and Its Isoforms in Cancer
Xianhui Wang, Leila Kokabee, Mostafa Kokabee, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 34
DNA Microarrays in Herbal Drug Research
Preeti Chavan, Kalpana Joshi, Bhushan Patwardhan
Evidence-based Complementary and Alternative Medicine (2006) Vol. 3, Iss. 4, pp. 447-457
Open Access | Times Cited: 73
Milestones and Monitoring in Patients with CML Treated with Imatinib
Michael W. Deininger
Hematology (2008) Vol. 2008, Iss. 1, pp. 419-426
Open Access | Times Cited: 71
Emerging stem cell concepts for imatinib‐resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease
Peter Valent
British Journal of Haematology (2008) Vol. 142, Iss. 3, pp. 361-378
Open Access | Times Cited: 62
Mechanisms of resistance to BCR–ABL kinase inhibitors
Joana Diamond, Junia V. Melo
Leukemia & lymphoma/Leukemia and lymphoma (2011) Vol. 52, Iss. sup1, pp. 12-22
Open Access | Times Cited: 59
Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia
Hamid Ali Nagi Al‐Jamal, Siti Asmaa Mat Jusoh, Rosline Hassan, et al.
BMC Cancer (2015) Vol. 15, Iss. 1
Open Access | Times Cited: 47
Genetic Biomarkers in Chronic Myeloid Leukemia: What Have We Learned So Far?
Bilal Abdulmawjood, Beatriz Costa, Catarina Roma‐Rodrigues, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 22, pp. 12516-12516
Open Access | Times Cited: 27
Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia
Guntram Buesche, Arnold Ganser, Brigitte Schlegelberger, et al.
Leukemia (2007) Vol. 21, Iss. 12, pp. 2420-2427
Closed Access | Times Cited: 61
Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells
Hardik Modi, Tinisha McDonald, Su Chu, et al.
Blood (2007) Vol. 109, Iss. 12, pp. 5411-5421
Open Access | Times Cited: 55
Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib
Marta Gromicho, Marta Magalhães, Fátima Torres, et al.
Oncology Reports (2012) Vol. 29, Iss. 2, pp. 741-750
Open Access | Times Cited: 43
Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era?
Ewelina Trela, Sylwester Głowacki, Janusz Błasiak
ISRN Oncology (2014) Vol. 2014, pp. 1-9
Open Access | Times Cited: 41
Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib
Chung Hoow Kok, David T Yeung, Lu Liu, et al.
Blood Advances (2019) Vol. 3, Iss. 10, pp. 1610-1621
Open Access | Times Cited: 33
BCR-ABL Activity Is Critical for the Immunogenicity of Chronic Myelogenous Leukemia Cells
Katharina M. Brauer, Daniela Werth, Karin von Schwarzenberg, et al.
Cancer Research (2007) Vol. 67, Iss. 11, pp. 5489-5497
Open Access | Times Cited: 51
Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia
Zheng Hu, Xiaofen Pan, Fuqun Wu, et al.
PLoS ONE (2009) Vol. 4, Iss. 7, pp. e6257-e6257
Open Access | Times Cited: 43
Chronic Myelogenous Leukemia
Susan O’Brien, Camille N. Abboud, Mojtaba Akhtari, et al.
Journal of the National Comprehensive Cancer Network (2012) Vol. 10, Iss. 1, pp. 64-110
Open Access | Times Cited: 37
Page 1 - Next Page

Scroll to top